Award-winning Mexican restaurant to open new tequila bar
The brothers who run Halisco, on Preston Street, will transform the GungHo cocktail bar, just across the street, into a new tequila bar.
The current GungHo bar will close on February 16, with work to create the new Halisco tequila bar to start soon after. The new bar is set to open in March.
Mexican restaurant Halisco is run by brothers Ali and Mo.
They announced the news on Instagram, writing: "We are opening a tequila bar!
"We've been regulars at GungHo ever since they opened, so thank you to everyone involved for the great times we've had."
GungHo cocktail bar is right across the street from Halisco (Image: Google) The brothers went on to explain their vision for the new bar.
"Picture Halisco vibes, but this time you're in a bar, not a restaurant.
"Expect an extensive list of Halisco margaritas, both tequila and mezcal based.
"Also, a banging menu of croquettes and some naughty ceviches throughout the summer.
"We're absolutely buzzing for this one, and we strongly feel this is the missing monopoly piece we needed on Preston Street."
A year ago the brothers opened Anakuma restaurant, also in Preston Street.
GungHo gave their blessing to the new enterprise, saying that Halisco would be "bringing some fresh energy into this legendary spot on the fiercely independent Preston Street.
"We are looking forward to seeing this space taking on a new life."
They picked up the "Eat Well For Less" award at the Brighton Restaurant Awards 2024, and were named as the third best restaurant in Brighton by TimeOut.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
28 minutes ago
- Business Insider
AI startup Perplexity is raising more money at a $20 billion valuation
Perplexity is raising yet another round of funding, Business Insider has learned. The AI search engine is seeking a fresh fundraise at a $20 billion post-money valuation, according to an email sent to prospective investors seen by BI, and a source with knowledge of the raise. It's been a busy year for Perplexity, which has become one of AI's hottest startups with funding from investors including SoftBank, Nvidia, and Jeff Bezos. Perplexity just made a $34.5 billion bid for Google's Chrome browser earlier this week, and it's been contending with analysts urging Apple to buy the booming startup for months. The new valuation represents a $2 billion jump from Perplexity's most recent valuation of $18 billion in its latest fundraising round in July, as first reported by Bloomberg last month. That's up from a $520 million valuation in January 2024. All the while, Perplexity's business has been surging. The startup, which launched in 2022 to combine large-language models with web searches to provide real-time answers to user questions, boosted its annual recurring revenue above $150 million by the middle of 2025. That's more than quadruple its roughly $35 million in ARR a year ago, according to the email seen by BI. Perplexity head of communication Jesse Dwyer said Perplexity is currently doing more than $150 million in ARR. He didn't answer further questions for this story. Perplexity is facing fierce competition from Big Tech giants like Google — the startup announced its own AI-native browser Comet last month — alongside AI leaders like OpenAI, which is reportedly working on its own web browser. It's not clear who's set to lead the latest funding round. Perplexity has raised about $1.5 billion to date, according to PitchBook. The $20 billion valuation Perplexity is seeking, while a meaningful lift for the company, still doesn't come close to the $34.5 billion Perplexity offered this week to buy Chrome from Google. Google hasn't signaled any intent to sell the browser, despite facing pressure from the Department of Justice to divest Chrome over antitrust concerns. Perplexity told The Wall Street Journal it has received commitments from several investors, including large venture capital funds, to fund the transaction, though it didn't disclose the names of those investors. Many have dismissed the bid as little more than a marketing stunt. "It makes them seem like a big player and helps them with fundraising, talent, and user attention by staying in the news cycle," one VC, who is not an investor in Perplexity, said. Perplexity has also sidestepped rumors that it could make a deal with Apple as the iPhone maker falls behind in the AI race. Dan Ives, managing director and equity research analyst at Wedbush Securities, said acquiring Perplexity should be a "no-brainer deal" for the tech behemoth. "For Apple, time is ticking," he told BI. Dwyer said at the time that the team was "unaware of any M&A discussions that involve Perplexity."
Forbes
an hour ago
- Forbes
Chrome As The Next AI Battleground? Experts Weigh In
Perplexity's $34.5 billion bid to buy Google's Chrome browser seems shocking at first glance. The AI firm has an estimated value of $18 billion — roughly half its offer price for Chrome. But the bid reaches beyond reality. This isn't a stunt around a browser. It's an attempt to seize the gate to the internet. And it's occurring at a time when Google may be forced by the courts to slip its grip on key assets — such as Chrome. AI Seeks To Shift The Center Of Gravity For Online Search In the old web, you searched, clicked and browsed. In the new web, you just ask — and let the AI take care of the rest. 'One of the biggest ideas emerging in AI is the Single Interface Experience,' said Piers Fawkes, founder of tech advisory firm PSFK and AI startup, ServiceBuddy. 'Unlike the Google era, where you'd search and then browse multiple sites, the SIE keeps you inside the AI, which then researches, books and buys on your behalf.' That's a revolution. Browsers are no longer dumb pipes. They're intelligent agents. The user who's driving the interface is driving the experience. And that's why Chrome matters now more than ever. 'For the average Chrome user, there may be no big change at first,' Fawkes said. 'But over time, AI could be baked into every browsing moment — comparison shopping, booking flights, even finding a mechanic — without leaving the browser.' In that world, Chrome's 70% share of global search is more than dominance. It's distribution for the next generation of AI. It's the high ground. AI Startup Is Punching Above Its Weight Class Perplexity's offer is more than a buyout bit. It's symbolic. A challenge flag waved at Google, already on the griddle for potentially overstepping on browser dominance. 'A federal court has ruled that Google holds an illegal search monopoly,' said Usha Haley, the W. Frank Barton Distinguished Chair in International Business & Professor of Management at the Barton School of Business at Wichita State University. 'The U.S. Justice Department may force divestiture of Chrome.' That's not hearsay. It's one option presented as part of the DOJ's antitrust case. Chrome could become a liability that Google has to divest. And if that happens, Perplexity wants first crack. Haley calls Perplexity's move 'strategically audacious, though unlikely to succeed.' But she adds that 'an AI-focused company acquiring Chrome brings new risks around data usage and privacy.' Perplexity has already said it will use browsing context to refine user profiles. Google Needs Chrome More Than Most Realize – So Do AI Companies "Chrome isn't just a browser," said Rich Pleeth, who was the UK and European Chrome marketing leader and is founder of AI-based delivery route optimizer, Finmile. 'It's the quiet lever that underpins Google's search and advertising dominance.' Chrome comes with Google search. That saves Alphabet billions of dollars every year in traffic acquisition costs. No Apple payments. No sweetheart deals with Mozilla. Just free, straight search volume. 'Based on retained search revenue alone, Chrome's value could easily exceed $100 billion,' Pleeth said. But he says it's not just search. Chrome feeds information to Google's whole ecosystem, from YouTube to Maps to Ads. That feedback loop makes ad targeting more precise, improves ad ranking and locks in user behavior. If Google loses Chrome, it doesn't lose a product. It loses clout, a rich data mining asset and access to lots of revenue. 'Chrome as a structural pillar of Google's business model is unbelievably valuable,' Pleeth added. 'Selling it would fundamentally weaken Google.' AI Firms See The Real Fight Is Over Discovery Who shows up when someone searches for a product, book a vacation or look for a plumber? That's the gatekeeper power. And that power is shifting from websites to AI front-ends. 'If an AI front-end controls the experience, it controls which brands and businesses get surfaced,' Fawkes said. 'That's the power play here — it's not just about owning a browser, it's about owning the point of access to the internet in the AI age.' Haley agrees. "E-commerce, travel, local services and even content publishers" could be worse off. According to her, ad networks could be heavily impacted while Bing, DuckDuckGo and even Amazon's Alexa could be harmed. OpenAI's ChatGPT has a head start. Gemini is catching up. Perplexity doesn't want to be left behind. 'Perplexity knows they risk becoming the Ask Jeeves of this generation,' Fawkes said. 'By buying the most popular browser, they can become the default SIE.' That's the bet. Outrageous. Risky. Probably impossible. But if Google is forced to sell Chrome, the question won't be whether or not Perplexity can afford it. The question will be whether a bidding war ensues among AI firms for this crown jewel of internet search.
Yahoo
2 hours ago
- Yahoo
Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge
The Mexico Microcarrier Market is poised for significant growth, projected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, achieving a CAGR of 7.66% from 2025 to 2033. Key drivers include increased investment in regenerative medicine and cell therapy, rising demand for cell-based vaccines and biologics, and technological advancements in cell culture efficiency. Mexico's biopharmaceutical sector expansion, supported by enhanced bioprocessing infrastructure and strategic public-private partnerships, further bolsters this growth. Emerging challenges include high setup costs and complex regulatory requirements, offering opportunities for innovation and collaboration. Mexican Microcarrier Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Mexico Microcarrier Market to Reach US$ 77.65 Million by 2033 - 7.66% CAGR Growth Driven by Biopharma Demand" report has been added to Mexico Microcarrier Market is expected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, with a CAGR of 7.66% from 2025 to 2033. Growing investment in regenerative medicine and cell therapy, growing demand for cell-based vaccines and biologics, technological advancements in culture efficiency, and expansion of biopharmaceutical research and development in Mexico. Mexico's growing biopharmaceutical and biotechnology industries depend heavily on the microcarrier industry. The large-scale manufacturing of biologics, vaccines, and cell treatments depends on microcarriers, which are tiny, spherical particles that promote the proliferation of adherent cells in bioreactors. As Mexico looks to improve its local manufacturing capabilities in response to growing healthcare demands and the need for medical product self-sufficiency, these applications become more and more market is expanding due to a number of causes. Research and development expenditures, along with the nation's strategic efforts to strengthen its biomanufacturing infrastructure, are essential. The need for effective cell culture systems is further fueled by the aging population and the rising incidence of chronic diseases, which increase demand for cutting-edge treatment solutions. Additionally, Mexico has easier access to cutting-edge biotechnologies, such as microcarrier-based cell culture systems, thanks to its involvement in international health programs and collaborations with foreign the encouraging growth trajectory, the Mexican microcarrier market still confronts obstacles including the requirement for specialized technological know-how and the development of strong regulatory frameworks to guarantee the quality and safety of the products. Nonetheless, these difficulties offer chances for creativity and cooperation. These problems can be resolved by creating training initiatives, establishing regulatory guidelines, and encouraging public-private partnerships. This will create an atmosphere that is favorable for the expansion of the microcarrier market and the larger biopharmaceutical sector in Factors Driving the Mexico Microcarrier Market Growth Increasing Demand for Cell Therapy and BiopharmaceuticalsMicrocarrier systems are in high demand due to Mexico's growing biopharmaceutical industry, which includes the manufacture of vaccines, biologics, and cell treatments. Businesses are depending more and more on microcarriers to sustain high density adherent cell cultures in bioreactors as local R&D becomes more intense and manufacturing capacity need is particularly noticeable in the creation of therapeutic proteins, monoclonal antibodies, and items related to regenerative medicine. Scalable and effective cell culture is made possible by microcarriers, which is necessary for the commercial production of biologics and sophisticated cell culture systems are now a vital enabling technology for Mexico's biomanufacturing efforts as the nation develops its capacities in these fields and aligns with international health Development and Manufacturing ExpansionMexico's bioprocessing infrastructure is being quickly strengthened through government sponsored initiatives and strategic public-private partnerships. The adoption of effective cell culture technologies is being fueled by investments in upstream bioprocessing facilities, automation, single use systems, and digital technology is also supported by the growth of industry academia partnership and regulatory modernization (e.g., COFEPRIS's digital transformation). These advancements promote easier technology transfer from research to production and improve the technical preparedness required for microcarrier is therefore better able to scale complex bioprocesses, which increases the accessibility of microcarriers for biotechnology companies, contract manufacturers, and academic institutions seeking to increase their capacity for and Technological Progress in MicrocarriersPerformance and scalability have been greatly enhanced by innovations in microcarrier design, such as surface functionalized beads, biodegradable materials, and compatibility with single use bioreactors. Manufacturers who prioritize quality and cost effectiveness are placing a greater value on enhanced features like increased yield, better cell adhesion, and lower contamination developments, when combined with automation, intelligent sensor integration, and digital process control, reduce human error and streamline production. Modern microcarrier formats are becoming feasible choices for biomanufacturers and researchers nation wide due to Mexico's rising alignment with international industry trends and the country's expanding adoption of state of the art bioprocessing in the Mexico Microcarrier Market Expensive Startup and Ongoing CostsMicrocarrier based cell culture system deployment requires a large financial outlay, especially for equipment such as bioreactors, single use systems, and associated infrastructure. Traditional planar culture techniques are still less expensive at lower scales because they require less like microcarrier beads make up a significant portion of the continuous expenses for microcarrier setups, which frequently require tens or even hundreds of thousands of dollars in capital expenditure. GMP grade, high quality microcarriers can account for 20-25% of total consumable financial barriers, in addition to media supplies and labor training, make the technology hard to adopt in Mexico, where a large number of biotech companies and academic institutions have tight budgets. Despite the long term productivity and efficiency benefits of microcarriers, this hinders scale of Regulations and Documentation NeedsUnder the General Health Law, COFEPRIS is in charge of regulating microcarrier based cell culture in Mexico, particularly when it is meant for clinical or therapeutic applications. In accordance with ICH guidelines, businesses are required to compile comprehensive Common Technical Document (CTD) dossiers that include clinical, non clinical, and quality is necessary to adhere to Official Mexican Standards (such as NOM?257?SSA1?2014, NOM?059?SSA1?2015), especially those that deal with GMP, bio comparability, and safety assessment. Microcarrier systems need to be thoroughly validated, which includes testing for batch uniformity, sterility, and cell material obstacles to commercialization include the burden of complicated documentation and testing, changing regulations, and unclear advanced therapeutic standards. Market access may be delayed, more expensive, and unclear for entities without local regulatory partnerships or past dossier experience. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Thermo Fisher Scientific Merck KGaA Eppendorf AG Danaher Corporation Sartorius AG Bio Rad Laboratories, Inc. Corning Inc. Lonza Group Getinge Becton, Dickinson and Company Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $39.96 Million Forecasted Market Value (USD) by 2033 $77.65 Million Compound Annual Growth Rate 7.6% Regions Covered Mexico Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Mexico Microcarrier Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Application6.3 By End User6.4 By Region7. Product Type7.1 Consumables7.1.1 Microcarrier Beads7.1.2 Media & Reagents7.2 Equipment8. Application8.1 Cell Therapy8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Vaccine Manufacturing8.3 Others9. End User9.1 Pharmaceutical & Biotechnology Companies9.2 Contract Research Organizations & Contract Manufacturing Organizations9.3 Academic & Research Institutes10. Region10.1 Northern Mexico10.2 Central Mexico10.3 Southern Mexico10.4 Others11. Value Chain Analysis12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Competition12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threats14. Pricing Benchmark Analysis14.1 Thermo Fisher Scientific14.2 Merck KGaA14.3 Eppendorf AG14.4 Danaher Corporation14.5 Sartorius AG14.6 Bio-Rad Laboratories, Inc.14.7 Corning Inc.14.8 Lonza Group14.9 Getinge14.10 Becton, Dickinson and Company15. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Mexican Microcarrier Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
